We are live on ! Find out more
AIM

AIM ImmunoTech

32 hedge funds and large institutions have $590K invested in AIM ImmunoTech in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 3232 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

36% less capital invested

Capital invested by funds: $919K → $590K (-$329K)

Holders
32
Holders Change
Holders Change %
0%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
4
Reduced
4
Closed
6
Calls
Puts
Net Calls
Net Calls Change

AIM Hedge Fund Activity: Q1 2025 in Review

32 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2025, worth a combined $590K — down 36% from $919K a quarter earlier.

Fund positioning in AIM was balanced in Q1 2025: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $73.3K. The largest seller was Citadel Advisors, cutting an estimated $49.9K.

  • 32 institutional investors held AIM ImmunoTech (AIM) as of Q1 2025, unchanged from Q4 2024.
  • Funds reported $590K of AIM ImmunoTech stock for Q1 2025, down 36% quarter-over-quarter.
  • 6 funds opened new AIM ImmunoTech positions in Q1 2025 and 6 closed out, a net change of 0 holders.
  • The largest AIM ImmunoTech buyer in Q1 2025 was Vanguard Group, an estimated $73.3K added.
  • The largest AIM ImmunoTech seller in Q1 2025 was Citadel Advisors, an estimated $49.9K sold.

Based on aggregated 13F filings for Q1 2025.